Some Research on Pregnant and Postpartum Women with HIV Is Presented at CROI, But More Trials Are Needed
Pregnant people who are living with or vulnerable to HIV need to be included in clinical trials in order to close our knowledge gaps.
HVTN 702 may not have proven an effective vaccine, but scientists still learned from the research.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.
COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.
Retire? No, Thanks! This Doc Instead Moved to West Virginia to Fight HIV, Hepatitis C, and the Opioid Crisis
In a poor and conservative state, Judith Feinberg, M.D., aims to expand harm reduction—and bring treatment to active drug users.
Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.
HVTN 702 is but one of many vaccine trials underway, researchers note.